The objective of the IMMUNITAS project is to develop Allergen-specific ImmunoTherapy (GlycoTx), based on complex sugars of the body, for the treatment of allergic dermatitis in dogs. Professor Yvette van Kooyk received the Spinoza Prize for this groundbreaking science in 2019. To confirm the positive effects of our innovative GlycoTxT in allergic dogs, GlycoTreat, in collaboration with the Veterinary University of Utrecht, has developed a range of experiments in which the tolerogenic effect of GlycoTx on the immune system can be measured using specific immune cells and biomarkers from blood of allergic dogs. In addition, the effectiveness of GlycoTx will be confirmed in a clinical study in dogs (patients) with allergic dermatitis in which the optimal dosage, safety and effectiveness will be determined. GlycoTreat aims to bring this treatment to the market in 2028.